An electrophysiological classification associated with Guillain–Barré syndrome outcomes

详细信息    查看全文

• 作者：Takafumi Hosokawa ; Hideto Nakajima ; Kiichi Unoda ; Kazushi Yamane…
• 关键词：Guillain–Barré syndrome ; AIDP ; AMAN ; Reversible conduction failure ; Outcome ; Electrophysiology
• 刊名：Journal of Neurology
• 出版年：2014
• 出版时间：October 2014
• 年：2014
• 卷：261
• 期：10
• 页码：1986-1993
• 全文大小：213 KB
• 参考文献：1. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (1995) Guillain–Barré syndrome in northern China. Relationship to / Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118(Pt 3):597-05 CrossRef
  2. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW (1986) An acute axonal form of Guillain–Barré polyneuropathy. Brain 109(Pt 6):1115-126 CrossRef
  3. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, Wu HS, Zhaori G, Liu Y, Jou LP et al (1993) Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33:333-42 CrossRef
  4. Yuki N, Hartung HP (2012) Guillain–Barré syndrome. N Engl J Med 366:2294-304 CrossRef
  5. Kuwabara S, Yuki N (2013) Axonal Guillain–Barré syndrome: concepts and controversies. Lancet Neurol 12:1180-188 CrossRef
  6. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M (1998) IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain–Barré syndrome. Ann Neurol 44:202-08 CrossRef
  7. Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A (2003) Acute motor conduction block neuropathy Another Guillain–Barré syndrome variant. Neurology 61:617-22 CrossRef
  8. Hiraga A, Kuwabara S, Ogawara K, Misawa S, Kanesaka T, Koga M, Yuki N, Hattori T, Mori M (2005) Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain–Barré syndrome. Neurology 64:856-60 CrossRef
  9. Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N (2010) Conduction block in acute motor axonal neuropathy. Brain 133:2897-908 CrossRef
  10. Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T (1998) Two patterns of clinical recovery in Guillain–Barré syndrome with IgG anti-GM1 antibody. Neurology 51:1656-660 CrossRef
  11. Uncini A, Manzoli C, Notturno F, Capasso M (2010) Pitfalls in electrodiagnosis of Guillain–Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 81:1157-163 CrossRef
  12. Kuwabara S, Ogawara K, Misawa S, Koga M, Mori M, Hiraga A, Kanesaka T, Hattori T, Yuki N (2004) Does / Campylobacter jejuni infection elicit “demyelinating-Guillain–Barré syndrome? Neurology 63:529-33 CrossRef
  13. Kuwabara S, Ogawara K, Misawa S, Mizobuchi K, Sung JY, Kitano Y, Mori M, Hattori T (2004) Sensory nerve conduction in demyelinating and axonal Guillain–Barré syndromes. Eur Neurol 51:196-98 CrossRef
  14. Sekiguchi Y, Uncini A, Yuki N, Misawa S, Notturno F, Nasu S, Kanai K, Noto Y, Fujimaki Y, Shibuya K, Ohmori S, Sato Y, Kuwabara S (2012) Antiganglioside antibodies are associated with axonal Guillain–Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 83:23-8 CrossRef
  15. The Italian Guillain-Barré Study Group (1996) The prognosis and main prognostic indicators of Guillain–Barré syndrome. A multicentre prospective study of 297 patients. Brain 119 (Pt 6):2053-061
  16. The Emilia-Romagna Study group on Clinical and Epidemiological Problems in Neurology (1997) A prospective study on the incidence and prognosis of Guillain–Barré syndrome in Emilia-Romagna region, Italy (1992-1993). Neurology 48:214-21
  17. Chio A, Cocito D, Leone M, Giordana MT, Mora G, Mutani R (2003) Guillain–Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology 60:1146-150 CrossRef
  18. McKhann GM, Griffin JW, Cornblath DR, Mellits ED, Fisher RS, Quaskey SA (1988) Plasmapheresis and Guillain–Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 23:347-53 CrossRef
  19. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meche FG (1999) Prognostic factors of Guillain–Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain–Barré Study Group. Neurology 53:598-04 CrossRef
  20. Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol 27(Suppl):S21–S24 CrossRef
  21. Yuki N, Kokubun N, Kuwabara S, Sekiguchi Y, Ito M, Odaka M, Hirata K, Notturno F, Uncini A (2012) Guillain–Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 259:1181-190 CrossRef
  22. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750-53 CrossRef
  23. Kimura J (1989) electrodiagnosis in diseases of nerve and muscle: principles and practice. F.A Davis, Philadelphia
  24. Isose S, Kuwabara S, Kokubun N, Sato Y, Mori M, Shibuya K, Sekiguchi Y, Nasu S, Fujimaki Y, Noto Y, Sawai S, Kanai K, Hirata K, Misawa S (2009) Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst 14:151-58 CrossRef
  25. Kalita J, Misra UK, Das M (2008) Neurophysiological criteria in the diagnosis of different clinical types of Guillain–Barré syndrome. J Neurol Neurosurg Psychiatry 79:289-93 CrossRef
  26. American Association of Electrodiagnostic M, Olney RK (1999) Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve Suppl 8:S225–S229
  27. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ (1993) Severe axonal degeneration in acute Guillain–Barré syndrome: evidence of two different mechanisms? J Neurol Sci 116:185-92 CrossRef
  28. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK (1996) Pathology of the motor-sensory axonal Guillain–Barré syndrome. Ann Neurol 39:17-8 CrossRef
  29. Yuki N (2001) Infectious origins of, and molecular mimicry in, Guillain–Barré and Fisher syndromes. Lancet Infect Dis 1:29-7 CrossRef
  30. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N (2000) Axonal Guillain–Barré syndrome: relation to anti-ganglioside antibodies and / Campylobacter jejuni infection in Japan. Ann Neurol 48:624-31 CrossRef
  31. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (1993) A bacterium lipopolysaccharide that elicits Guillain–Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178:1771-775 CrossRef
  32. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, Taguchi K, Miyatake T, Furukawa K, Kobata T, Yamada M (2004) Carbohydrate mimicry between human ganglioside GM1 and / Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc Natl Acad Sci USA 101:11404-1409 CrossRef
  33. Clouston PD, Kiers L, Zuniga G, Cros D (1994) Quantitative analysis of the compound muscle action potential in early acute inflammatory demyelinating polyneuropathy. Electroencephalogr Clin Neurophysiol 93:245-54 CrossRef
  34. Baba M, Matsunaga M (1984) Recovery from acute demyelinating conduction block in the presence of prolonged distal conduction delay due to peripheral nerve constriction. Electromyogr Clin Neurophysiol 24:611-17
  35. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, Hirata K, Baba H, Yuki N (2007) Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27:3956-967 CrossRef
  36. Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK (1996) Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain–Barré syndrome. J Neurocytol 25:33-1 CrossRef
  37. Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, Funakoshi K, Rasband MN (2012) Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233:534-42 CrossRef
  38. Kaida K, Sonoo M, Ogawa G, Kamakura K, Ueda-Sada M, Arita M, Motoyoshi K, Kusunoki S (2008) GM1/GalNAc-GD1a complex: a target for pure motor Guillain–Barré syndrome. Neurology 71:1683-690 CrossRef
  39. Kusunoki S, Kaida K (2011) Antibodies against ganglioside complexes in Guillain–Barré syndrome and related disorders. J Neurochem 116:828-32 CrossRef
  40. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S (2003) Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes. Neurology 61:471-74 CrossRef
  41. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC (2007) A clinical prognostic scoring system for Guillain–Barré syndrome. Lancet Neurol 6:589-94 CrossRef
  42. Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC (2011) Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology 76:968-75 CrossRef
  
• 作者单位：Takafumi Hosokawa (1)
  Hideto Nakajima (1)
  Kiichi Unoda (1)
  Kazushi Yamane (1)
  Yoshimitsu Doi (1)
  Shimon Ishida (1)
  Fumiharu Kimura (1)
  Toshiaki Hanafusa (1)
  
  1. Department of Internal Medicine I, Osaka Medical College, Daigakumachi 2-7, Takatsuki, Osaka, 569-8686, Japan
  
• ISSN：1432-1459

文摘

Guillain–Barré syndrome (GBS) is an acute, post-infectious, inflammatory, autoimmune peripheral neuropathy with a highly diverse clinical course and outcome. We classified GBS on the basis of patients-first nerve conduction and validated this system to be associated with outcome on the basis of electrophysiological characteristics during the acute phase of GBS. We retrospectively evaluated 40 GBS patients who underwent their first electrophysiological study within 14?days of onset and classified GBS into four patterns: (1) acute inflammatory demyelinating polyneuropathy (AIDP) pattern with sensory nerve conduction abnormalities (motor–sensory AIDP: MS-AIDP), (2) AIDP pattern without sensory nerve conduction abnormalities (motor AIDP: M-AIDP), (3) acute motor axonal neuropathy (AMAN) pattern, and (4) minor abnormalities pattern. We compared the clinical, electrophysiological, and laboratory findings between groups and determined subgroups associated with poor outcome. The MS-AIDP and AMAN patterns more frequently exhibited prolonged recovery compared with the M-AIDP and minor abnormalities patterns and were associated with prolonged recovery (specificity, 100?%; sensitivity, 73?%; P?AIDP and AMAN patterns than in the M-AIDP and minor abnormalities patterns (median 85 vs. 10?days; P?